stockrow
Monday 9 November 2026
Export ADRX’s income statement to Excel — free account
ADARx Pharmaceuticals, Inc.
ADRX
13.23
0.06
−0.45%
Follow ADRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | 6 | 40 | 40 | +158.7% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 100 | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 7 Oct 2026
ADARx Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.6B | — (loss-making) | — (loss-making) | −1.42% (below 0%: shrinking) | n/m | +440.97% (above 0%: growing) | 99.34% | (13.31%) | Compare |
| PGEN Precigen, Inc. | $1.6B | 60.8× | 20.8× | +2,437.58% (above 0%: growing) | n/m | +138.86% (above 0%: growing) | 91.22% | 52.13% | Compare |
| NBTX Nanobiotix S.A. - Sponsored ADR | $1.6B | — (loss-making) | — | −71.69% (below 0%: shrinking) | n/m | −177.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QURE uniQure N.V. | $1.5B | — (loss-making) | — (loss-making) | +40.39% (above 0%: growing) | n/m | −192.89% (below 0%: shrinking) | 95.46% | (1,019.63%) | Compare |
| ADRX ADARx Pharmaceuticals, Inc. | $1.5B | — | — | — | — | — | — | — | |
| NUVB Nuvation Bio Inc. | $1.5B | — (loss-making) | — (loss-making) | +242.61% (above 0%: growing) | n/m | +34.07% (above 0%: growing) | 73.46% | (93.90%) | Compare |
| TYRA Tyra Biosciences, Inc. | $1.5B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OCUL Ocular Therapeutix, Inc. | $1.5B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| Median of peers | $1.5B | — | — | +20.25% | — | −3.80% | 85.08% | (13.31%) |